These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2531773)

  • 1. Efficacy, safety and tolerability of raclopride, a specific D2 receptor blocker, in acute schizophrenia: an open trial.
    Cookson JC; Natorf B; Hunt N; Silverstone T; Uppfeldt G
    Int Clin Psychopharmacol; 1989 Jan; 4(1):61-70. PubMed ID: 2531773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.
    Farde L; Wiesel FA; Jansson P; Uppfeldt G; Wahlen A; Sedvall G
    Psychopharmacology (Berl); 1988; 94(1):1-7. PubMed ID: 3126517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. The British Isles Raclopride Study Group.
    Acta Psychiatr Scand; 1992 Nov; 86(5):391-8. PubMed ID: 1485530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.
    Tauscher-Wisniewski S; Kapur S; Tauscher J; Jones C; Daskalakis ZJ; Papatheodorou G; Epstein I; Christensen BK; Zipursky RB
    J Clin Psychiatry; 2002 Nov; 63(11):992-7. PubMed ID: 12444812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
    Nordström AL; Farde L; Wiesel FA; Forslund K; Pauli S; Halldin C; Uppfeldt G
    Biol Psychiatry; 1993 Feb; 33(4):227-35. PubMed ID: 8097114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.
    Nordström AL; Farde L
    J Clin Psychopharmacol; 1998 Aug; 18(4):305-10. PubMed ID: 9690696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia.
    Wiesel FA; Nordström AL; Farde L; Eriksson B
    Psychopharmacology (Berl); 1994 Feb; 114(1):31-8. PubMed ID: 7846205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
    Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
    J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
    Csernansky JG; Newcomer JW; Jackson K; Lombrozo L; Faull KF; Zipursky R; Pfefferbaum A; Faustman WO
    Psychopharmacology (Berl); 1994 Nov; 116(3):291-6. PubMed ID: 7534423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new selective D2-dopamine receptor antagonist raclopride--pharmacokinetics, safety and tolerability in healthy males.
    Farde L; von Bahr C; Wahlen A; Nilsson L; Widman M
    Int Clin Psychopharmacol; 1989 Apr; 4(2):115-26. PubMed ID: 2526172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.
    Kapur S; Remington G; Jones C; Wilson A; DaSilva J; Houle S; Zipursky R
    Am J Psychiatry; 1996 Jul; 153(7):948-50. PubMed ID: 8659621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia--a study group report.
    Delini-Stula A; Berdah-Tordjman D
    J Psychiatr Res; 1996; 30(4):239-50. PubMed ID: 8905533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
    Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
    Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients.
    McEvoy JP; Movin-Osswald G; Uppfeldt G; Williams T; Dutcher S; Apperson J
    Psychopharmacology (Berl); 1993; 112(2-3):371-4. PubMed ID: 7871044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.
    Borison RL; Arvanitis LA; Miller BG
    J Clin Psychopharmacol; 1996 Apr; 16(2):158-69. PubMed ID: 8690831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
    Chabannes JP; Pelissolo A; Farah S; Gerard D
    Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.